
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called AEB071 for people with diffuse large B cell lymphoma (DLBCL) that has come back after treatment.
Doctors can treat DLBCL with chemotherapy, radiotherapy or both. But sometimes the lymphoma starts to grow again. When this happens it is often more difficult to treat.
AEB071 is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
The aims of this trial are to find out
Your lymphoma will be tested to find out if it has a change to the CD79 gene. You will not be able to take part in this trial if your lymphoma cells do not have this change.
You may be able to enter this trial if you
You cannot enter this trial if you
There are 2 parts to this phase 1 trial. Everybody taking part will have AEB071 daily.
In the first part of the trial, the researchers are trying to work out the best dose of AEB071 to give. The first few patients will have a low dose. If they don’t have any serious side effects, the next few patients will have a higher dose. And so on, until the researchers find the highest dose that can be given safely. This is called a dose escalation study.
Once they’ve found the highest safe dose, the researchers want to learn more about how AEB071 works. You continue to take the tablets daily until your lymphoma starts to grow again or you do not want to continue. The dose will depend on when you joined the trial.
If you agree to take part in this study, the researchers will ask for a sample of tissue taken when you had surgery to diagnose your cancer. If this is not available you will need to have a . Doctors need this to test for the CD79 gene.
You will see the doctors and have some tests before you start treatment. The tests include
You will see the doctors and have heart, blood and urine tests frequently while you are taking AEB071.
You have CT scans every 8 weeks for 6 months then every 3 months until your cancer starts to grow again.
You see the doctors 30 days after you stop the AEB071. This is the last trial visit.
As AEB071 is a new drug, there may be some side effects we don’t know about yet. The possible side effects that researchers already know about include
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor J A Radford
Experimental Cancer Medicine Centre (ECMC)
Novartis
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”